The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.

Abstract

Histone deacetylase (HDAC) inhibitors have attracted much interest because of their ability to arrest cell growth, induce cell differentiation, and in some cases, induce apoptosis of cancer cells. In the present study, we have examined a new HDAC inhibitor, suberic bishydroxamate (SBHA), for its effect on a panel of human melanoma cell lines. We report that it induces varying degrees of apoptosis in the melanoma lines but not in melanocytes and fibroblasts. Induction of apoptosis was caspase dependent and was associated with induction of changes in mitochondrial membrane permeability, which could be inhibited by overexpression of Bcl-2. The changes in mitochondria were independent of caspase activation and were associated with changes in conformation of Bax. SBHA down-regulated several key antiapoptotic proteins including X-linked inhibitor of apoptosis and the Bcl-2 family proteins, Bcl-XL and Mcl-1. In contrast, it induced up-regulation of the Bcl-2 family proapoptotic proteins, Bim, Bax, and Bak. In addition, SBHA induced relocation of the protein Bim to mitochondria and its association with Bcl-2. De novo protein synthesis was required for initiation of apoptosis in that the protein synthesis inhibitor, cycloheximide, inhibited SBHA-induced conformational changes in Bax as well as changes in mitochondrial membrane permeability and activation of caspase-3. These results suggest that SBHA induces apoptosis by changing the balance between proapoptotic and antiapoptotic proteins in melanoma cells. The protein Bim may be a key initiator of apoptosis in cells treated with SBHA.

• Authors: Xu Dong Zhang, Susan K Gillespie, Jodie M Borrow, Peter Hersey
• Journal: Molecular cancer therapeutics (Mol Cancer Ther) Vol. 3 Issue 4 Pg. 425-35 (Apr 2004) ISSN: 1535-7163 [Print] United States
• PMID: 15078986 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Amino Acid Chloromethyl Ketones
• Apoptosis Regulatory Proteins
• BAK1 protein, human
• BAX protein, human
• BCL2L1 protein, human
• BCL2L11 protein, human
• Bcl-2-Like Protein 11
• Carrier Proteins
• Caspase Inhibitors
• Cysteine Proteinase Inhibitors
• Enzyme Inhibitors
• Histone Deacetylase Inhibitors
• Hydroxamic Acids
• Membrane Proteins
• Myeloid Cell Leukemia Sequence 1 Protein
• Neoplasm Proteins
• Oligopeptides
• Proteins
• Proto-Oncogene Proteins
• Proto-Oncogene Proteins c-bcl-2
• X-Linked Inhibitor of Apoptosis Protein
• XIAP protein, human
• bcl-2 Homologous Antagonist-Killer Protein
• bcl-2-Associated X Protein
• bcl-X Protein
• benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone
• benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
• suberic bishydroxamate
• CASP3 protein, human
• Caspase 3
• Caspases
• Histone Deacetylases

Topics

• Amino Acid Chloromethyl Ketones (pharmacology)
• Apoptosis (drug effects)
• Apoptosis Regulatory Proteins
• Bcl-2-Like Protein 11
• Carrier Proteins (metabolism)
• Caspase 3
• Caspase Inhibitors
• Caspases (metabolism)
• Cell Line, Tumor
• Cysteine Proteinase Inhibitors (pharmacology)
• Enzyme Inhibitors (pharmacology)
• Histone Deacetylase Inhibitors
• Histone Deacetylases (metabolism)
• Humans
• Hydroxamic Acids (pharmacology)
• Intracellular Membranes (metabolism)
• Melanoma (pathology)
• Membrane Proteins (metabolism)
• Mitochondria (drug effects, metabolism)
• Myeloid Cell Leukemia Sequence 1 Protein
• Neoplasm Proteins (metabolism)
• Oligopeptides (pharmacology)
• Permeability (drug effects)
• Protein Conformation (drug effects)
• Protein Transport (drug effects)
• Proteins (metabolism)
• Proto-Oncogene Proteins (metabolism)
• Proto-Oncogene Proteins c-bcl-2 (chemistry, metabolism)
• X-Linked Inhibitor of Apoptosis Protein
• bcl-2 Homologous Antagonist-Killer Protein
• bcl-2-Associated X Protein
• bcl-X Protein